StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 12, 2026, 04:15 PM

Nkarta Q1 Net Loss Narrows to $27.8M; Operating Expenses Down

AI Summary

Nkarta, Inc. reported a narrower net loss of $27.8 million for the first quarter of 2026, an improvement from the $32.0 million loss in the same period last year, primarily driven by a significant reduction in general and administrative expenses. The company's total operating expenses decreased to $30.9 million. However, cash and cash equivalents, along with total current assets, saw a decline compared to the end of 2025, and the accumulated deficit grew to $676.1 million.

Key Highlights

  • Net loss narrowed to $27.8 million in Q1 2026 from $32.0 million in Q1 2025.
  • Net loss per share improved to $(0.37) in Q1 2026 from $(0.43) in Q1 2025.
  • Total operating expenses decreased to $30.9 million in Q1 2026 from $36.6 million in Q1 2025.
  • General and administrative expenses significantly decreased to $5.9 million from $12.4 million year-over-year.
  • Cash and cash equivalents were $27.4 million as of March 31, 2026, down from $39.6 million at Dec 31, 2025.
  • Total current assets decreased to $235.9 million as of March 31, 2026 from $282.5 million at Dec 31, 2025.
  • Accumulated deficit reached $676.1 million as of March 31, 2026.
  • Management believes current funds are sufficient for at least twelve months from the filing date.